Table 2.

CTX and TRAP5b serum levels in controls and patients.

	Controls	NDMM with active bone disease	NDMM w/o active bone disease	Responders with active bone disease	Responders w/o active bone disease	At relapse with active bone disease	At relapse w/o active bone disease	PD with active bone disease	PD w/o active bone disease
TRAP5b	1.67 ± 0.27	3.21 ± 0.45	1.67 ± 0.26	2.30 ± 0.38	1.09 ± 0.29	3.52 ± 0.61	1.56 ± 0.09	2.82 ± 0.38	1.21 ± 0.05
P < 0.001	§p < 0.05	*p < 0.05		*p < 0.05		*p < 0.05		*p < 0.05
CTX	0.32 ± 0.03	0.51 ± 0.07	0.25 ± 0.02	0.26 ± 0.02	0.22 ± 0.05	0.51 ± 0.07	0.26 ± 0.01	0.23 ± 0.1	0.22 ± 0.03
P < 0.006	§p < 0.05	*p < 0.05				*p < 0.05

P < 0.001 for comparison of all groups (one-way ANOVA on ranks), and P < 0.05 (Dunn's post-hoc test).

^§Controls vs. NDMM;

^*Patients with vs. w/o bone disease.

Newly diagnosed multiple myeloma (NDMM); progressive disease (PD); C-terminal telopeptide of collagen type 1 (CTX); Tartrate-resistant acid phosphatase 5b (TRAP5b)